Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam Inc. has a promising outlook due to its innovative technology that allows for the remote monitoring of cardiac patients, with an annual revenue potential of approximately $1,200 to $1,500 per patient. The company has achieved significant regulatory milestones, including FDA clearance for its ECG solutions, positioning it for commercial rollout while expanding its clinical evidence and patent portfolio. Management's strategy anticipates an increase in total addressable market through integration into cardiology networks and telemedicine platforms, with a pathway to cash-flow breakeven achievable with the enrollment of around 30,000 patients.

Bears say

HeartBeam Inc faces significant challenges that could impede its revenue growth, particularly due to the potential inability to achieve sufficient patient penetration within medical practices. The integration of HeartBeam's proprietary technology into existing clinical workflows may lead to slower-than-expected physician adoption, which can adversely impact commercial success. Additionally, the risk of competition and potential challenges to the company's intellectual property could undermine its competitive positioning in the medical technology market.

HeartBeam (BEAT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.